We are live on
!
Find out more
Rockefeller Capital Management Portfolio holdings
AUM
$56.4B
1-Year Est. Return
24.96%
This Fund
S&P 500
This Quarter
Est. Return
+16.85%
1 Year Est. Return
+24.96%
3 Year Est. Return
+83.53%
5 Year Est. Return
+100.91%
10 Year Est. Return
–
AUM
$13.2B
AUM Growth
+$2.53B
(+24%)
Cap. Flow
+$1B
Cap. Flow
% of AUM
7.59%
Top 10 Holdings %
Top 10 Hldgs %
23.93%
Holding
3,118
New
401
Increased
1,400
Reduced
617
Closed
168
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alibaba
BABA
|
+$120M |
| 2 |
Globe Life
GL
|
+$115M |
| 3 |
MPT
Medical Properties Trust
MPT
|
+$91.5M |
| 4 |
Arch Capital
ACGL
|
+$69.2M |
| 5 |
Amazon
AMZN
|
+$45.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Progressive
PGR
|
+$138M |
| 2 |
GSK
GSK
|
+$98.7M |
| 3 |
Crown Holdings
CCK
|
+$92.3M |
| 4 |
American Water Works
AWK
|
+$54M |
| 5 |
SolarEdge
SEDG
|
+$45.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.64% |
| 2 | Financials | 15.05% |
| 3 | Healthcare | 13.07% |
| 4 | Consumer Discretionary | 9.61% |
| 5 | Communication Services | 7.75% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1001
iShares MSCI China ETF
MCHI
$6.38B
| $378K | ﹤0.01% |
4,685
+3,564
| +318% | +$282K |
|
1002
Alphatec Holdings
ATEC
$1.44B
| $377K | ﹤0.01% |
26,000
| – | – |
|
1003
iShares US Pharmaceuticals ETF
IHE
$1.64B
| $377K | ﹤0.01% |
6,309
+6
| +0.1% | +$342 |
|
1004
StoneCo
STNE
$2.58B
| $377K | ﹤0.01% |
+4,500
| New | +$301K |
|
1005
Beyond Meat
BYND
$277M
| $375K | ﹤0.01% |
3,003
+1,214
| +68% | +$183K |
|
1006
iShares ESG Aware MSCI EM ETF
ESGE
$6.73B
| $375K | ﹤0.01% |
8,949
+4,629
| +107% | +$180K |
|
1007
WisdomTree US High Dividend Fund
DHS
$1.58B
| $374K | ﹤0.01% |
5,402
+5,302
| +5,302% | +$354K |
|
1008
Royal Caribbean
RCL
$85.6B
| $373K | ﹤0.01% |
5,012
+2,691
| +116% | +$188K |
|
1009
Markel Group
MKL
$23.2B
| $371K | ﹤0.01% |
360
-39
| -10% | -$38.9K |
|
1010
Northern Trust
NTRS
$33.9B
| $371K | ﹤0.01% |
3,992
-29,435
| -88% | -$2.6M |
|
|
TECX
1011
Tectonic Therapeutic
TECX
$606M
| $371K | ﹤0.01% |
2,221
| – | – |
|
1012
D.R. Horton
DHI
$42.3B
| $369K | ﹤0.01% |
5,367
-24
| -0.4% | -$1.75K |
|
1013
Vanguard S&P 500 Value ETF
VOOV
$6.74B
| $368K | ﹤0.01% |
2,982
+34
| +1% | +$3.98K |
|
1014
VanEck Fallen Angel High Yield Bond ETF
ANGL
$3.11B
| $366K | ﹤0.01% |
11,431
+705
| +7% | +$21.8K |
|
|
GOCO
1015
DELISTED
GoHealth
GOCO
| $363K | ﹤0.01% |
+1,773
| New | +$329K |
|
1016
Vail Resorts
MTN
$5.3B
| $363K | ﹤0.01% |
1,304
-120
| -8% | -$31K |
|
1017
C.H. Robinson
CHRW
$17.5B
| $362K | ﹤0.01% |
3,863
-1,703
| -31% | -$162K |
|
1018
First Trust Managed Municipal ETF
FMB
$2.06B
| $362K | ﹤0.01% |
6,384
+2,672
| +72% | +$150K |
|
1019
QuantumScape Corp
QS
$3.74B
| $361K | ﹤0.01% |
+4,281
| New | +$157K |
|
1020
Cohen & Steers Quality Income Realty Fund
RQI
$1.69B
| $360K | ﹤0.01% |
29,032
+24,507
| +542% | +$286K |
|
1021
Arrowhead Research
ARWR
$12.4B
| $358K | ﹤0.01% |
4,672
+46
| +1% | +$2.94K |
|
1022
Yum China
YUMC
$16.3B
| $358K | ﹤0.01% |
6,287
+468
| +8% | +$26.3K |
|
|
CDK
1023
DELISTED
CDK Global, Inc.
CDK
| $358K | ﹤0.01% |
6,952
+387
| +6% | +$18.4K |
|
|
CYBR
1024
DELISTED
CyberArk
CYBR
| $356K | ﹤0.01% |
2,211
+73
| +3% | +$8.49K |
|
1025
Schwab Short-Term US Treasury ETF
SCHO
$12.9B
| $356K | ﹤0.01% |
13,874
+306
| +2% | +$7.87K |
|
Similar funds
NAMI
Rockefeller Capital Management's Q4 2020 Portfolio in Review
As of Q4 2020, Rockefeller Capital Management held 3,118 positions worth $13.2B, up 24% from $10.7B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Rockefeller Capital Management deployed $1B of net new capital in Q4 2020, opening 401 new positions and adding to 1,400 existing holdings. Its largest new stake was BridgeBio Pharma: 777,031 shares worth $55.3M.
By sector, the portfolio is most concentrated in Technology at 21% of assets, down from 21% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was Progressive, an estimated $138M trimmed.
- Rockefeller Capital Management's largest Q4 2020 buy was BridgeBio Pharma: 777,031 shares worth $55.3M.
- Rockefeller Capital Management added most to Alibaba in Q4 2020, an estimated $120M increase.
- Rockefeller Capital Management's biggest Q4 2020 reduction was Progressive, cutting an estimated $138M.
- Rockefeller Capital Management fully exited Unilever NV New York Registry Shares in Q4 2020, selling an estimated $1.67M.
- Rockefeller Capital Management's ten largest holdings make up 24% of its $13.2B portfolio in Q4 2020.
- Rockefeller Capital Management opened 401 new positions and closed 168 in Q4 2020.
- Rockefeller Capital Management's portfolio value rose 24% quarter-over-quarter to $13.2B.
Based on Rockefeller Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.